MMR vaccine injections into lesions for stubborn ringworm of the body and groin (tinea corporis and cruris)
Official title: Evaluating the Therapeutic Efficacy of Intra-lesional Immunotherapy Against Recalcitrant Tinea Cruris & Corporis: a Pilot Study
Run by Mansoura University Hospital · NCT07312604 · Data updated 2026-11-12
This pilot will test whether injecting the MMR vaccine into affected skin can help people ages 10–60 with tinea corporis or cruris that hasn't responded to standard antifungal treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 10 Years to 60 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Mansoura University Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Al Mansurah, Dakahlia Governorate) |
| Status | Recruiting |
| Started | December 9, 2025 |
| Main results expected | March 9, 2026 |
| Study ends | March 9, 2026 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT07312604 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 10–60 with recalcitrant tinea corporis or cruris who have failed at least two courses of systemic antifungals in the past three months and can attend scheduled clinic visits.
✕Probably not a fit
Patients who are pregnant or breastfeeding, immunocompromised, naïve to systemic antifungal therapy, or unable/unwilling to attend follow-up visits are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot interventional study gives intra-lesional MMR vaccine injections into the active borders of affected tinea lesions every two weeks for up to six weeks, with a repeat course allowed if only partial improvement occurs. Pulse oral itraconazole is given during the first two weeks of treatment. Eligible participants are 10–60 years old with recalcitrant tinea defined by rapid progression, large or multiple-family involvement, rapid relapse, suspected resistant strains, or failure of at least two systemic antifungal courses in the past three months. The trial will track clinical clearance and safety at a single center (Mansoura University Hospital) as a preliminary test of this immune-based approach.
Why it matters
Potential benefit: If successful, this approach could provide a local immune-based option to clear dermatophyte infections that do not respond to standard antifungals, potentially reducing relapses and long courses of systemic therapy.
How similar studies have gone: Small case reports and pilot series have reported benefit from intralesional immunotherapies for persistent skin infections, but large controlled trials specifically using MMR for recalcitrant dermatophytosis are lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 10 - 60 years. * Evidence of recalcitrant tinea e.g. (rapid progression \& large areas affected of the body, affection of more than one family members especially females \& children, rapid relapse after treatment, suspicion of resistant T. indotineae strain by history of traveling abroad \& contact with Indians or contact with a case coming from travel \& with contact to Indians. * Patients failed at least 2 courses of systemic antifungal therapy in the last 3 months. * Safe contraception during the study (for females in the childbearing period). Exclusion Criteria: * Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception. * Age \<10 years or \> 60 years. * Immunocompromised patients e.g. (uncontrolled DM or HIV patients). * Naïve patients without previous systemic antifungal treatment. * Unreliable patients.
Where it's running
-
Mansoura University Hospital
Al Mansurah, Dakahlia Governorate, Egypt Recruiting
Study contacts
- Study coordinator: Abeer Mohamed Elkholy, MD degree of Dermatology
- Email: abeerkholy@hotmail.com
- Phone: +201006210646
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dermatophyte antifungal susceptibility in Faisalabad: terbinafine and itraconazole MICs
This study tests how common skin fungus infections in Faisalabad respond to terbinafine and itraconazole by measuring the lowest drug levels that stop growth in patient samples.
-
Fluconazole versus itraconazole for resistant ringworm (tinea corporis)
This study will test whether oral fluconazole or oral itraconazole works better to clear persistent tinea corporis in adults who have had the infection for at least six months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.